Radiopeptides Analogues of Somatostatin Used for the Treatment of Neuroendocrine Tumors - Literature Review


  • Fagner Santos do Carmo Laboratory of Nanoradiopharmaceuticals, Rio de Janeiro, Brazil
  • Marta de Souza Albernaz Laboratory of Nanoradiopharmaceuticals, Rio de Janeiro, Brazil
  • Ralph Santos-Oliveira Laboratory of Nanoradiopharmaceuticals, Rio de Janeiro, Brazil



Radiopharmaceuticals, peptides, endocrinology, neuroendocrine tumors.


 The use of somatostatin analogues is growing each year, especially for tumor imaging and treatment. In this scenario the numbers of radionuclides and the perspective of new one are quite promising. In this review we approach the possibilities and give an overview of the trends and possibilities in this area.


Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.

Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis 2004; 36(suppl 1): S106-S120.

Vogelstein B, Kinzler KE. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-799.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.

Rindi G, Capella C, Solcia E. Introduction to a revised clinic pathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000; 44(1): 13-21.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.

Kaltsas G, Mukherjee JJ, Plowman PN, Grossman AB. The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clin Endocrinol (Oxf) 2001; 55(5): 575-87.

Modlin IM, Zikusoka M, Kidd M, Latich I, Eick G, Romanyshyn J. The history and epidemiology of neuroendocrine tumors. In: Caplin M, Kvols L, eds. Handbook of Neuroendocrine Tumors. 1st ed. Bristol, UK: BioScientifica 2006; pp. 7-37.

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. UKNETwork for Neuroendocrine Tumours: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. GUT 2005; 54(SUPPL 4): IV1-16.

Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AKC, Modlin IM. Neuroendocrine tumor epidemiology. Contrasting Norway and North America. Cancer 2008; 113: 10.

Mamikunian G, Vinik A, O’Dorisio TM, Woltering EA, Liang VWG. Neuroendocrine Tumors. A Comprehensive Guide to Diagnosis and Management. 4th ed. Inter Science Institute 2009.

Patel YC. General aspects of the biology and function of somatostatin. In Well C, Muller EE, Eds. Basic and Clinical Aspects of Neurosciences. Berlin: Springer-Verlag 1992; pp. 1-6.

Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.

Reichlin S. Somatostatin I and II. N Engl J Med 1983; 309: 1495-501, 1556-63.

Reubi JC, Hacki WH, Lamberts SW. Hormone producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987; 65: 1127-34.

Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helhoe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine-tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv 2002; 440: 461-75.

Janson ET, Stridsberg M, GobL A, Westlin JE, Öberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998; 58: 2375-8.

Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997; 41: 63-70.

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-846.

Kwekkeboom DJ, Kam BL, Martijn van Essen, Teunissen JJM, van Eijck CHJ, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17: R53-R73.

Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin Receptor Scintigraphy. New York, NY: Raven Press 1995; pp. 1-50.

Reubi JC, Mäcke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46(Suppl. 1): 67-75.

Kwekkeboom DJ, De Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-30.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-23.

Thulin L, Samnegård H, Tydén G, Long DH, Efendic S. Efficacy of somatostatin in a patient with a carcinoid syndrome. Lancet 1978; 2: 43.

Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94: 1381-7.

Fjällskog ML, Sundin A, Westlin JE, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002; 19: 35-42.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPAd-Phe1]- and [123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.

Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 2001; 47(Suppl. 2): 1-29.

Sundin A, Vullierme MP, Kaltsas G, Plöckinger U. Mallorca Consensus Conferenceparticipants; European Neuroen-docrine Tumor Society. ENETS Consensus ENETS. Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-83.

Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. Oncology Committee of the EANM. 111In-Pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010; 37(7): 1441-8.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. PROMID Study Group. Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.

Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Acta Oncol 2004; 43(7): 617-25.

Krenning EP, De Jong M, Kooij PP, Breeman WA, Bakker WH, De Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10(2): 23-29.

Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995; 25(3): 272-8.

Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 2011; 52: 841-4.

De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, et al. Pre-clinical comparison of [DTPAo,Try3] octreotide and [DTPA0, D-PhelTry3] as carriers somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75: 406-411.<406::AID-IJC14>3.0.CO;2-6

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.

Oberg K. Future aspects of somatostatin- receptor- mediated therapy. Neuroendocrinology 2004; 80: 57-61.

Ambrosini A, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011; 52(12) (Suppl).

Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7: 971-994.

Thundimadathil J. Cancer Treatment Using Peptides: Current Therapies and Future Prospects. J Amino Acids 2012; Article ID 967347, 13 pages.

Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008; 15(3): 701-720.

Nicolas G, Giovacchini G, MÜller-Brand J, Forrer F. Targeted radiotherapy with radiolabeled somatostatinanalogs. Endocrinol Metab Clin North Am 2011; 40(1): 187-204.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)] octreotate. Eur J Nucl Med Mol Imaging 2003; 30: 417-422.

Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28: 426-434.

Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.<227::AID-CNCR2820680202>3.0.CO;2-I

Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Harder WW, et al. Somatostatin receptor: Scintigraphy and radionuclide therapy. Digestion 1996; 57(S1): 57-61.

Kwekkeboom DJ, Krenning EP, de Jong M. Peptidereceptor imaging and therapy. J Nucl Med 2000; 41: 1704-1713.

Schwartz AL, Fridovich SE, Lodish HF. Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem 1982; 257: 4230-4237.

Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Antiproliferative effect of radiolabelled octretide in metastases model in rat liver. Int J Cancer 1999; 81: 767-771.<767::AID-IJC17>3.0.CO;2-T

McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In pentetreotide: state of the art and perspectives. Q J Nucl Med 2000; 44: 88-95.

Meyers MO, Anthony LB, McCarthy KE, Drouant G, Maloney TJ, et al. High-dose indium 111In pentetreotide radiotherapy foe metastatic atypical carcinoid tumor. South Med J 2000; 93: 809-811.

Martin RF, Bradley TR, Hodgson GS. Cytotoxicity of a 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Res 1979; 39: 3244-3247.

De Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.

Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999; 40: 762-767.

O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36: 1902-1909.

De Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, et al. Tumor response after [(90)YDOTA(0), Tyr(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42: 1841-1846.

Baum RP, Söldner J, Schmücking M, Niesen A. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) usingY-90 -DOTA-Tyr 3 -octreotate (Y-90- DOTATATE) in patients with metastatic neuroendocrine tumors (abstract). Eur J Nucl Med 2004; 31(suppl 2): S238.

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32: 148-155.

De Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, et al. Comparison of (111) In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58(3): 437-41.

Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.

Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwekkeboom DJ. Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0),Tyr (3)] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33: 1346-1351.

Waldherr C, Pless M, Mäcke HR, Haldemann A, Müller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-5.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-62.

Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12: 683-699.

Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem90Y/177Lu- DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 2011; 38: 1788-1797.

Bodei L. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. J Endocrinol Invest 2009; ISBN: 978-90-367-3769-2.

Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111- pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32(2): 123-32.

Graham MM, Menda Y. Radiopeptide Imaging and Therapy in the United States. J Nucl Med 2011; 52: 56S-63S.

Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 2010; 14: 347-351.

Kam BL, Teunissen JJM, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39(Suppl 1): S103-S112.

Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21(1): 111-129.




How to Cite

Fagner Santos do Carmo, Marta de Souza Albernaz, & Ralph Santos-Oliveira. (2014). Radiopeptides Analogues of Somatostatin Used for the Treatment of Neuroendocrine Tumors - Literature Review. Journal of Analytical Oncology, 3(1),  46–52.